Aug 16, 2012 8:00am EDT Tonix Pharmaceuticals CEO Dr. Seth Lederman Describes Potential Treatment for Fibromyalgia, Post-Traumatic Stress Disorder and Traumatic Brain Injury
Aug 14, 2012 8:00am EDT Tonix Pharmaceuticals Reports That Sublingual Formulation of Fibromyalgia Drug Reduces Production of a Psychoactive Metabolite, Improving Suitability for Long-Term, Chronic Treatment
Jul 30, 2012 8:00am EDT Tonix Pharmaceuticals Announces Completion of Clinical Trial of Sublingual TNX-102
Jun 27, 2012 11:00am EDT Tonix Pharmaceuticals to Present at LHA Life Sciences & Medical Technologies Virtual Conference on June 28
Jun 27, 2012 8:00am EDT Tonix Pharmaceuticals Receives Health Canada Clearance to Study a Novel Treatment for Fibromyalgia
